1
项与 阿达木单抗生物类似药(Mabscale) 相关的临床试验Randomized Double Blind Phase III Trial Comparative Clinical Safety, Efficacy and Immunogenicity of Adalimumab (Manufactured by Mabscale, LLC) to Humira®.
MABPS-3/2020 is a double-blind randomized multicenter clinical trial comparing efficacy, immunogenicity and safety profiles of Adalimumab (manufactured by Mabscale, LLC) compared to Humira®.
The purpose of the study is to demonstrate efficacy, immunogenicity and safety of Adalimumab (manufactured by Mabscale, LLC) to Humira ® in adult patients with chronic plaque psoriasis of moderate and severe degree.
100 项与 阿达木单抗生物类似药(Mabscale) 相关的临床结果
100 项与 阿达木单抗生物类似药(Mabscale) 相关的转化医学
100 项与 阿达木单抗生物类似药(Mabscale) 相关的专利(医药)
100 项与 阿达木单抗生物类似药(Mabscale) 相关的药物交易